Hamsters Protected from SARS-CoV-2 Delta Variant Challenge after Two Doses of Adjuvanted SARS-CoV-2 Recombinant Spike Protein (S-2P) and One Dose of Beta S-2P( )

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern negatively impact the effectiveness of vaccines. In this study, we challenge hamsters with the delta variant after 2- or 3-dose inoculations with SARS-CoV-2 vaccines constructed from stabilized prefusion spike proteins...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuo, Tsun-Yung, Lien, Chia En, Lin, Yi-Jiun, Lin, Meei-Yun, Wu, Chung-Chin, Tang, Wei-Hsuan, Campbell, John D, Traquina, Paula, Chuang, Ya-Shan, Liu, Luke Tzu-Chi, Cheng, Jinyi, Chen, Charles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047188/
https://www.ncbi.nlm.nih.gov/pubmed/35451470
http://dx.doi.org/10.1093/infdis/jiac153
_version_ 1784695677107830784
author Kuo, Tsun-Yung
Lien, Chia En
Lin, Yi-Jiun
Lin, Meei-Yun
Wu, Chung-Chin
Tang, Wei-Hsuan
Campbell, John D
Traquina, Paula
Chuang, Ya-Shan
Liu, Luke Tzu-Chi
Cheng, Jinyi
Chen, Charles
author_facet Kuo, Tsun-Yung
Lien, Chia En
Lin, Yi-Jiun
Lin, Meei-Yun
Wu, Chung-Chin
Tang, Wei-Hsuan
Campbell, John D
Traquina, Paula
Chuang, Ya-Shan
Liu, Luke Tzu-Chi
Cheng, Jinyi
Chen, Charles
author_sort Kuo, Tsun-Yung
collection PubMed
description Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern negatively impact the effectiveness of vaccines. In this study, we challenge hamsters with the delta variant after 2- or 3-dose inoculations with SARS-CoV-2 vaccines constructed from stabilized prefusion spike proteins (S-2P) of Wuhan (W) and beta (B) variants. Compared to 3 doses of W S-2P, 2 doses of W S-2P followed by a third dose of B S-2P induced the highest neutralizing antibody titer against live SARS-CoV-2 virus and enhanced neutralization of omicron variant pseudovirus. Reduced lung live virus titer and pathology suggested that all vaccination regimens protect hamsters from SARS-CoV-2 delta variant challenge.
format Online
Article
Text
id pubmed-9047188
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-90471882022-04-28 Hamsters Protected from SARS-CoV-2 Delta Variant Challenge after Two Doses of Adjuvanted SARS-CoV-2 Recombinant Spike Protein (S-2P) and One Dose of Beta S-2P( ) Kuo, Tsun-Yung Lien, Chia En Lin, Yi-Jiun Lin, Meei-Yun Wu, Chung-Chin Tang, Wei-Hsuan Campbell, John D Traquina, Paula Chuang, Ya-Shan Liu, Luke Tzu-Chi Cheng, Jinyi Chen, Charles J Infect Dis Brief Report Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern negatively impact the effectiveness of vaccines. In this study, we challenge hamsters with the delta variant after 2- or 3-dose inoculations with SARS-CoV-2 vaccines constructed from stabilized prefusion spike proteins (S-2P) of Wuhan (W) and beta (B) variants. Compared to 3 doses of W S-2P, 2 doses of W S-2P followed by a third dose of B S-2P induced the highest neutralizing antibody titer against live SARS-CoV-2 virus and enhanced neutralization of omicron variant pseudovirus. Reduced lung live virus titer and pathology suggested that all vaccination regimens protect hamsters from SARS-CoV-2 delta variant challenge. Oxford University Press 2022-04-22 /pmc/articles/PMC9047188/ /pubmed/35451470 http://dx.doi.org/10.1093/infdis/jiac153 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Report
Kuo, Tsun-Yung
Lien, Chia En
Lin, Yi-Jiun
Lin, Meei-Yun
Wu, Chung-Chin
Tang, Wei-Hsuan
Campbell, John D
Traquina, Paula
Chuang, Ya-Shan
Liu, Luke Tzu-Chi
Cheng, Jinyi
Chen, Charles
Hamsters Protected from SARS-CoV-2 Delta Variant Challenge after Two Doses of Adjuvanted SARS-CoV-2 Recombinant Spike Protein (S-2P) and One Dose of Beta S-2P( )
title Hamsters Protected from SARS-CoV-2 Delta Variant Challenge after Two Doses of Adjuvanted SARS-CoV-2 Recombinant Spike Protein (S-2P) and One Dose of Beta S-2P( )
title_full Hamsters Protected from SARS-CoV-2 Delta Variant Challenge after Two Doses of Adjuvanted SARS-CoV-2 Recombinant Spike Protein (S-2P) and One Dose of Beta S-2P( )
title_fullStr Hamsters Protected from SARS-CoV-2 Delta Variant Challenge after Two Doses of Adjuvanted SARS-CoV-2 Recombinant Spike Protein (S-2P) and One Dose of Beta S-2P( )
title_full_unstemmed Hamsters Protected from SARS-CoV-2 Delta Variant Challenge after Two Doses of Adjuvanted SARS-CoV-2 Recombinant Spike Protein (S-2P) and One Dose of Beta S-2P( )
title_short Hamsters Protected from SARS-CoV-2 Delta Variant Challenge after Two Doses of Adjuvanted SARS-CoV-2 Recombinant Spike Protein (S-2P) and One Dose of Beta S-2P( )
title_sort hamsters protected from sars-cov-2 delta variant challenge after two doses of adjuvanted sars-cov-2 recombinant spike protein (s-2p) and one dose of beta s-2p( )
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047188/
https://www.ncbi.nlm.nih.gov/pubmed/35451470
http://dx.doi.org/10.1093/infdis/jiac153
work_keys_str_mv AT kuotsunyung hamstersprotectedfromsarscov2deltavariantchallengeaftertwodosesofadjuvantedsarscov2recombinantspikeproteins2pandonedoseofbetas2p
AT lienchiaen hamstersprotectedfromsarscov2deltavariantchallengeaftertwodosesofadjuvantedsarscov2recombinantspikeproteins2pandonedoseofbetas2p
AT linyijiun hamstersprotectedfromsarscov2deltavariantchallengeaftertwodosesofadjuvantedsarscov2recombinantspikeproteins2pandonedoseofbetas2p
AT linmeeiyun hamstersprotectedfromsarscov2deltavariantchallengeaftertwodosesofadjuvantedsarscov2recombinantspikeproteins2pandonedoseofbetas2p
AT wuchungchin hamstersprotectedfromsarscov2deltavariantchallengeaftertwodosesofadjuvantedsarscov2recombinantspikeproteins2pandonedoseofbetas2p
AT tangweihsuan hamstersprotectedfromsarscov2deltavariantchallengeaftertwodosesofadjuvantedsarscov2recombinantspikeproteins2pandonedoseofbetas2p
AT campbelljohnd hamstersprotectedfromsarscov2deltavariantchallengeaftertwodosesofadjuvantedsarscov2recombinantspikeproteins2pandonedoseofbetas2p
AT traquinapaula hamstersprotectedfromsarscov2deltavariantchallengeaftertwodosesofadjuvantedsarscov2recombinantspikeproteins2pandonedoseofbetas2p
AT chuangyashan hamstersprotectedfromsarscov2deltavariantchallengeaftertwodosesofadjuvantedsarscov2recombinantspikeproteins2pandonedoseofbetas2p
AT liuluketzuchi hamstersprotectedfromsarscov2deltavariantchallengeaftertwodosesofadjuvantedsarscov2recombinantspikeproteins2pandonedoseofbetas2p
AT chengjinyi hamstersprotectedfromsarscov2deltavariantchallengeaftertwodosesofadjuvantedsarscov2recombinantspikeproteins2pandonedoseofbetas2p
AT chencharles hamstersprotectedfromsarscov2deltavariantchallengeaftertwodosesofadjuvantedsarscov2recombinantspikeproteins2pandonedoseofbetas2p

Ejemplares similares